Research team photo with prize medal (L-R): Mr Paul Paddle, Dr. Stacy Goergen, Mr Guillermo Hurtado |
Led by Monash Health Ear Nose and Throat (ENT) surgeon Mr Paul Paddle,
the study investigated the diagnostic accuracy of an imaging technique, Non Echo-planar diffusion
weighted (non-EPI DWI) MRI in detecting recurrent cholesteatoma—an
abnormal skin growth in the middle ear behind the eardrum.
With
collaborators including Director of Research, Department of Imaging Professor Stacy Goergen, Monash
Health ENT surgeon Mr Guillermo Hurtado and Alfred Health ENT surgeon Professor Vince
Cousins, the blinded study also analysed the role of non-EPI DWI
MRI in surgical decision-making in cholesteatoma.
Temporal Bones CT scan shows left middle ear non-specific opacification |
“In an Australian-first, this study
validates the use of this specific MRI technique as an additional tool for the
management of cholesteatoma,” said Mr Hurtado.
Cholesteatoma is a common, non-malignant but destructive
lesion that can cause erosion
of bones such as the ossicles, the mastoid process or the skull base. Management
of cholesteatoma is challenging and requires complex middle ear surgery.
‘Cholesteatoma
can develop in up to 10% of people with chronic suppurative otitis media
(CSOM), a chronic inflammation of the middle ear and mastoid cavity,” said Mr
Hurtado.
“CSOM is a
major public health issue, with the World Health Organization estimating
between 65–330 million people worldwide being affected, mostly in the
developing world.”
“Imaging techniques such
as CT scan and MRI assist confirmation of clinical suspicion and postoperative
evaluation, however, differentiation of cholesteatoma from other types of
middle ear inflammation or postoperative changes is not yet available,” said Mr
Hurtado.
Currently, revision
surgery and histopathology analysis is the standard of care to exclude recurrence
of cholesteatoma disease.
“Conclusions from our study will aid in the
development of a formal cholesteatoma post-operative patient management
protocol at Monash Health ENT Department,” added Mr Hurtado.
“Further
research including additional cost-effectiveness analysis could potentially
lead to reducing healthcare costs for the management of our large group of
patients affected by cholesteatoma disease.”
No comments:
Post a Comment